Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025556 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Phase 2 study of Episodic Migraine Headache, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
- 20
- Study locations
NCT02025556: Completed Phase 2 study of Episodic Migraine Headache, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT02025556 is a Phase 2 study of Episodic Migraine Headache that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 297 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02025556, a Phase 2 study of Episodic Migraine Headache, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
Primary Outcome
A migraine day was endorsed when at least 1 of the following situations occurred: 1) A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache endorsing criteria for migraine, or 2) a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache endorsing criteria for probable migraine, a migraine subtype where only one migraine criterion is missing, or 3) the participant used acute migraine medication (triptans and ergot compounds) to treat
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LBR-101 High Dose
- DRUG LBR-101 Low Dose
Study Locations (20)
California
- Teva Investigational Site 161 - Anaheim
- Teva Investigational Site 116 - Fullerton
- Teva Investigational Site 119 - Long Beach
- Teva Investigational Site 146 - Oceanside
- Teva Investigational Site 113 - San Francisco
- Teva Investigational Site 108 - Stanford
- Teva Investigational Site 112 - Walnut Creek
Florida
- Teva Investigational Site 143 - DeLand
- Teva Investigational Site 137 - Hialeah
- Teva Investigational Site 159 - Hollywood
- Teva Investigational Site 101 - Jacksonville
- Teva Investigational Site 166 - Jacksonville
- Teva Investigational Site 129 - Maitland
- Teva Investigational Site 167 - Orlando
Arizona
- Teva Investigational Site 145 - Gilbert
- Teva Investigational Site 130 - Phoenix
- Teva Investigational Site 117 - Scottsdale
Arkansas
- Teva Investigational Site 158 - Little Rock
Colorado
- Teva Investigational Site 132 - Boulder
Connecticut
- Teva Investigational Site 162 - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2015-03-31 |
| Phase | Phase 2 |
What the finished NCT02025556 record still lists
NCT02025556 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (123% higher).
The record links to 1 condition, with Episodic Migraine Headache appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02025556 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02025556 about?
NCT02025556 is a clinical study titled "A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine". The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
What is the current status of trial NCT02025556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2014-01-31. Estimated completion is 2015-03-31.
What conditions does trial NCT02025556 study?
This clinical trial studies the following conditions: Episodic Migraine Headache.
What interventions are being tested in trial NCT02025556?
The interventions under investigation include: Placebo (DRUG), LBR-101 High Dose (DRUG), LBR-101 Low Dose (DRUG).
Who is sponsoring clinical trial NCT02025556?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02025556 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02025556's enrollment target sits among peer trials
297 188th of 2000 higher than 1,812 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI